COVID-19 is an ongoing global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus was first identified from an outbreak in the Chinese city of Wuhan in December 2019.1

For the first two years of the pandemic, no specific effective treatment or cure was available. In the first months of the pandemic, antiviral and immunomodulatory agents were proposed as potential treatments. Drugs such as hydroxychloroquine, lopinavir/ritonavir, ivermectin and azithromycin were reported and tested as potential therapeutic options.2 Azithromycin presented in vitro activity against SARS-CoV-2 and was able to act in different points of the viral cycle, with the main antiviral effect of azithromycin being due to its intracellular alkalizing effect. However, the evidence of its clinical use was always scarce and of low quality. A recent systematic review of the available clinical trials revealed that the routine use of azithromycin as therapy in Covid-19 patients was not justified, due to its lack of efficacy and potential risk of bacterial resistance that was not offset by an increased clinical benefit.3,4

The proarrhythmic effects of azithromycin are well known,5 resulting in prolonged ventricular repolarization, which associated with the tropism of SARS-CoV-2 for cardiomyocytes, has raised well-founded concerns regarding the use of this drug, particularly in association with hydroxychloroquine, as it could potentially lead to a severely prolonged QTc interval.6 Several of the therapeutic protocols even proposed the serial electrocardiographic monitoring of these patients. Several studies have since demonstrated the safety of the drug, within therapeutic doses, despite its ineffectiveness for its primary objective.

Regardless of these premises, and reporting from the last two years, the mass use of azithromycin has served as a laboratory experiment to assess the impact of the drug on certain electrocardiographic properties. In the current issue of this journal, Sunkak and et al.7 seek to detail the effects of azithromycin on ventricular repolarization in children with COVID-19. The study included 105 pediatric patients who were hospitalized between June and August 2020 in a single center Pediatric Infection Diseases Clinic, with a positive COVID-19 PCR test and treated with oral azithromycin. In this study, oral azithromycin had no effect on QTc, Tp-ec, QTc, or Tp-ec dispersion or the Tp-ec/QTc ratio in children with COVİD-19. Hence, in the authors experience, oral azithromycin treatment alone did not affect ventricular repolarization in children with COVID-19 and appeared to be safe in asymptomatic or mildly symptomatic patients.

Nevertheless, as we have previously stated, for hydroxychloroquine to be used in pediatric patients in the same setting,8 the direct cardiac toxicity of SARS-CoV-2 and the relative contribution of concomitant drugs to the reported cardiac adverse effects in COVID-19 patients needs to be further studied and be better evaluated.